3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
11
Observational
2
Sponsor
Cancer Type
Head & Neck
2
Conditions
Carcinoma, Hepatocellular
20
Carcinoma, Renal Cell
16
Liver Neoplasms
7
Leukemia, Myeloid, Acute
3
Thyroid Neoplasms
2
Financial Stress
2
Carcinoma
2
Patient Preference
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Adenoma, Islet Cell
1
Interventions
Thyroidectomy
5
Iodine-131
5
Surgical Procedures, Operative
3
selpercatinib
2
lenvatinib
2
anlotinib
2
Ultrasonography
2
Transurethral Resection of Prostate
2
Sorafenib
2
Molecular Diagnostic Techniques
2
Interviews as Topic
2
Focus Groups
2
Biopsy, Fine-Needle
2
trastuzumab deruxtecan
1
trametinib
1
pralsetinib
1
pembrolizumab
1
gallium Ga 68 dotatate
1
dabrafenib
1
Triiodothyronine
1
Thyroxine
1
Thyrotropin Alfa
1
Surveys and Questionnaires
1
Routinely Collected Health Data
1
Radiotherapy, Adjuvant
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Minimally Invasive Surgical Procedures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Observational
×
Thyroid Neoplasms
×
Sorafenib
×
Clear all
NCT02185560
2026-04-14
JPMS-DTC
Bayer
Active not recruiting
453 enrolled
NCT02303444
2023-06-08
RIFTOS MKI
Bayer
Completed
667 enrolled